Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

9.37
-0.0100-0.11%
Post-market: 9.370.00000.00%16:04 EDT
Volume:480.07K
Turnover:4.52M
Market Cap:512.35M
PE:-5.02
High:9.50
Open:9.37
Low:9.29
Close:9.38
Loading ...

Zevra Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
12 Mar

Zevra Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

Zevra Therapeutics Q4 Net Loss Widens, Revenue Decreases; Shares Fall After Hours

MT Newswires Live
·
12 Mar

Zevra Therapeutics FY 2024 GAAP EPS $(2.28) Misses $(1.99) Estimate, Sales $23.600M Beat $20.514M Estimate

Benzinga
·
12 Mar

Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects

Simply Wall St.
·
10 Mar

Zevra Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
08 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain

Simply Wall St.
·
04 Mar

Zevra Therapeutics: Strategic Growth and Financial Strength Drive Buy Rating

TIPRANKS
·
01 Mar

Zevra Launches New Disease State Awareness Campaign, ‘Learn Npc, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

THOMSON REUTERS
·
28 Feb

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

GlobeNewswire
·
28 Feb

BUZZ-Zevra Therapeutics rises on agreement to sell its FDA priority review voucher for $150 mln

Reuters
·
28 Feb

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million

Dow Jones
·
27 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA) and Venus Concept (VERO)

TIPRANKS
·
27 Feb

Zevra Therapeutics Enters Agreement to Sell Its Rare Pediatric Disease Priority Review Voucher for $150 Million

THOMSON REUTERS
·
27 Feb

Press Release: Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Dow Jones
·
27 Feb

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

GlobeNewswire
·
26 Feb

Zevra to Participate at Upcoming Investor Conferences

GlobeNewswire
·
25 Feb

Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM

TIPRANKS
·
10 Feb

Zevra Therapeutics price target raised to $21 from $20 at Guggenheim

TIPRANKS
·
04 Feb